(Q38253493)

1 September 2017

1 reference

title

Overlapping CNS inflammatory diseases: differentiating features of NMO and MS. (English)

1 reference

1 September 2017

3

Jacqueline Palace

1 reference

1 September 2017

1

Maciej Juryńczyk

1 reference

1 September 2017

Matthew Craner

2

1 reference

PubMed ID

25248365

1 September 2017

language of work or name

English

0 references

publication date

23 September 2014

1 reference

Journal of Neurology, Neurosurgery and Psychiatry

1 September 2017

1 reference

1 September 2017

86

1 reference

1 September 2017

1

1 reference

1 September 2017

20-25

1 reference

The spectrum of neuromyelitis optica

1 September 2017

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Multiple sclerosis in the Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Epidemiology of neuromyelitis optica in the United States: a multicenter analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Rapidly progressive course of very late onset multiple sclerosis presenting with Parkinsonism: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Effects of age and sex on aquaporin-4 autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Familial neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

NMO-IgG predicts the outcome of recurrent optic neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Visual field characteristics in neuromyelitis optica in absence of and after one episode of optic neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

CNS aquaporin-4 autoimmunity in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Magnetic resonance imaging in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Optical coherence tomography in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Revised diagnostic criteria for neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Mechanical ventilation and tracheostomy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Longitudinally extensive myelopathy in Caucasians: a West Australian study of 26 cases from the Perth Demyelinating Diseases Database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

The differential diagnosis of longitudinally extensive transverse myelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Increased radial diffusivity in spinal cord lesions in neuromyelitis optica compared with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Hypothalamic lesions in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Brain abnormalities in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

A population-based study of neuromyelitis optica in Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

No MRI evidence of cortical lesions in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

The clinical course of neuromyelitis optica (Devic's syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Muscle-specific kinase antibody positive myaesthenia gravis and multiple sclerosis co-presentation: a case report and literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: Results from 211 lumbar punctures

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Failure of natalizumab to prevent relapses in neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Does natalizumab therapy worsen neuromyelitis optica?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Natalizumab and the development of extensive brain lesions in neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

Preferential spinal central gray matter involvement in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2014-308984

21 January 2018

Identifiers

DOI

10.1136/JNNP-2014-308984

1 reference

1 September 2017

1 reference

PubMed ID

25248365